RecruitingPhase 3NCT05699174

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

PO Versus IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation


Sponsor

Major Extremity Trauma Research Consortium

Enrollment

250 participants

Start Date

May 30, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This is a Phase III clinical randomized control trial to investigate differences between patient with an infected nonunion treated by PO vs. IV antibiotics. The study population will be 250 patients, 18 years or older, being treated for infected nonunion after internal fixation of a fracture with a segmental defect less than one centimeter. Patients will be randomly assigned to either the treatment (group 1) PO antibiotics for 6 weeks or the control group (group 2) IV antibiotics for 6 weeks. The primary hypothesis is that the effectiveness of oral antibiotic therapy is equivalent to traditional intravenous antibiotic therapy for the treatment of infected nonunion after fracture internal fixation, when such therapy is combined with appropriate surgical management. Clinical effectiveness will be measured as the primary outcome as the number of secondary re-admissions related to injury and secondary outcomes of treatment failure (re-infection, nonunion, antibiotic complications) within the first one year of follow-up, as defined by specified criteria and determined by a blinded data assessment panel. In addition, treatment compliance, the cost of treatment, the number of surgeries required, the type and incidence of complications, and the duration of hospitalization will be measured.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Nonunion of a fracture that has previously undergone fixation. A Nonunion is defined as unplanned surgery with the primary purpose to promote union based on clinical/radiographic evidence >3 months after last fixation
  • Infection as determined by either
  • FRI criteria
  • CDC criteria (without the timeframe) This includes the possibility of culture negative, but determined to be infection by treating surgeon
  • Systemic antibiotic treatment regimen scheduled for at least 6 weeks

Exclusion Criteria9

  • Patients with a high risk of amputation based on the initial managing physician
  • Patients undergoing treatment of any other investigational therapy within the month preceding infection treatment or planned within the 12 months following infection treatment
  • Incarcerated or institutionalized patients
  • Patients who are unable to return for required follow-up visits and/or medical co-morbidities which preclude treatment with a general anesthetic
  • Patients with a prior history of chronic infection at the index site before fracture fixation
  • Patients with pathological fractures from a neoplastic process
  • History of Paget's Disease
  • The patient, or a designated proxy, unwilling to provide consent
  • The patient must be available for follow-up for at least 12 months following infection treatment

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGStandard of Care PO (oral) antibiotics

An intervention in this study includes randomization of patients with an infected nonunion to PO (oral) antibiotics for up to 6 weeks post hospitalization. The exact type of oral antibiotic will be depended on the patient's infection diagnosis.

DRUGStandard of Care Intravenous (IV) antibiotics

An intervention in this study includes randomization of patients with an infected nonunion to intravenous (IV) antibiotics for up to 6 weeks post hospitalization. The exact type of IV antibiotic will be depended on the patient's infection diagnosis.


Locations(13)

Indiana University

Indianapolis, Indiana, United States

University of Maryland , MD Department of Orthopaedics

Baltimore, Maryland, United States

Sinai Hospital Baltimore

Baltimore, Maryland, United States

Hennepin Health

Minneapolis, Minnesota, United States

Jamaica Hospital Medical Center

Queens, New York, United States

Atrium Health, Carolinas Medical Center

Charlotte, North Carolina, United States

Wake Forest University Baptist Medical Center

Winston-Salem, North Carolina, United States

University of Okalahoma College of Medicine

Oklahoma City, Oklahoma, United States

Penn State University M.S. Hershey Medical Center

Hershey, Pennsylvania, United States

Vanderbilt Medical Center

Nashville, Tennessee, United States

University of Texas Health Science Center at Houston

Houston, Texas, United States

University of Washington Harborview Medical Center

Seattle, Washington, United States

University of Wisconsin

Madison, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05699174


Related Trials